Follow the Structure Therapeutics Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on US US, under the oversight of SEC (Form 4). Market capitalisation: €3.4bn. The latest transaction was disclosed on 5 August 2026 (Levée d'options). Among the most active insiders: Lin Xichen. Every trade is accessible without an account.
48
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Structure Therapeutics Inc. Strong Buy (bullish), based on 15 analysts. Average price target: US$104.83.
31Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
6,441 shares@ US$7.916659.7% of flowOrdinary SharesSEC:0001415889-25-019352:0
25 of 48 declarations
About Structure Therapeutics Inc.
Structure Therapeutics Inc. is a biopharmaceutical company focused on developing treatments for metabolic diseases and health-related disorders. It employs a drug discovery platform to identify new therapies.